NCT06811272View on ClinicalTrials.gov

Outpatient Epcoritamab as 2L in NTE R/R DLBCL

PHASE2RecruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

June 5, 2025

Primary Completion Date

October 1, 2026

Study Completion Date

October 1, 2028

Conditions

Relapsed Large B-cell LymphomaRefractory Large B-cell Lymphoma

Interventions

DRUG

Epcoritamab

Bispecific IgG1 antibody

Trial Locations (2)

02114

NOT_YET_RECRUITING

Massachusetts General Hospital, Boston

02462

RECRUITING

Newton-Wellesley Hospital, Newton

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Genmab

INDUSTRY

lead

Massachusetts General Hospital

OTHER